AstraZeneca news - the latest biotech news from Labiotech.eu

FDA approves Beyfortus ahead of 2023-24 RSV season

Jim Cornall — Tue, 18 Jul 2023 08:28:06 +0000

The U.S. Food and Drug Administration (FDA) has approved Sanofi and AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The approval also covers children up to 24 months of age who remain vulnerable to severe […]

The post FDA approves Beyfortus ahead of 2023-24 RSV season appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

AstraZeneca non-small cell lung cancer drug meets primary endpoint

Jim Cornall — Thu, 06 Jul 2023 09:40:00 +0000

Positive high-level results from AstraZeneca’s TROPION-Lung01 phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy. […]

The post AstraZeneca non-small cell lung cancer drug meets primary endpoint appeared first on Labiotech.eu.

SandboxAQ launches new division to boost drug development

Jim Cornall — Fri, 23 Jun 2023 08:13:19 +0000

After several years of stealth development, SandboxAQ has announced its bio-pharma molecular simulation division, AQBioSim, and some of its customers. The division is helping bio-pharma and research institutions achieve breakthroughs in treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions. The company is currently working with biopharma companies and university research labs, including AstraZeneca, Sanofi and […]

The post SandboxAQ launches new division to boost drug development appeared first on Labiotech.eu.

Quell in potential $2B AstraZeneca cell therapy deal

Jim Cornall — Fri, 09 Jun 2023 08:33:35 +0000

Quell Therapeutics Ltd, a developer of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has entered into a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialize autologous, engineered Treg cell therapies for two autoimmune disease indications. “We are extremely pleased to have AstraZeneca on […]

The post Quell in potential $2B AstraZeneca cell therapy deal appeared first on Labiotech.eu.

Beyond Biotech podcast 47

Jim Cornall — Fri, 26 May 2023 08:47:26 +0000

The companies Daiichi Sankyo and AstraZeneca have worked together for several years. This week’s podcast is sponsored by Daiichi Sankyo and AstraZeneca. On this week’s podcast, we have a conversation with Markus Kosch, the head of Oncology Europe and Canada for Daiichi Sankyo, and Greg Rossi, Senior Vice President, Oncology, Europe and Canada, from AstraZeneca, who are joining […]

The post Beyond Biotech podcast 47 appeared first on Labiotech.eu.

World’s first RSV vaccine for older adults gets FDA approval

Jim Cornall — Thu, 04 May 2023 09:30:11 +0000

GSK plc says the US Food and Drug Administration (FDA) has approved Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. It is the first RSV vaccine for older adults to be approved anywhere in […]

The post World’s first RSV vaccine for older adults gets FDA approval appeared first on Labiotech.eu.

AstraZeneca creates FRAGLER for DNA synthesis

Jim Cornall — Thu, 02 Feb 2023 09:31:51 +0000

“Plasmids are critical for so many processes in early drug discovery,” says David Öling, associate principal scientist at AstraZeneca. “From protein production, cell line engineering, CAR-T cell therapy, viral vector generation, therapeutic genome editing, mRNA/vaccine production and more. The time it takes and the cost of producing plasmids for DNA constructs is a critical limiting […]

The post AstraZeneca creates FRAGLER for DNA synthesis appeared first on Labiotech.eu.

Ibex to collaborate with AstraZeneca and Daiichi Sankyo on AI breast cancer product

Jim Cornall — Thu, 26 Jan 2023 08:34:19 +0000

Ibex Medical Analytics has announced an agreement with AstraZeneca and Daiichi Sankyo, for the development, clinical validation and early adoption of an AI-powered product to aid pathologists with an accurate and reproducible assessment of HER2 immunohistochemistry (IHC) scoring in breast cancer patients. Scoring of HER2 (human epidermal growth factor receptor 2) protein expression in breast […]

The post Ibex to collaborate with AstraZeneca and Daiichi Sankyo on AI breast cancer product appeared first on Labiotech.eu.

Beyond Biotech podcast 30: Advanced Therapies Congress, BioAlps, Bionter, C2i Genomics

Jim Cornall — Fri, 20 Jan 2023 11:48:59 +0000

The guests on our podcast this week are: Jessica Robinson, project director, Advanced Therapies Congress, Terrapinn: Tobias Werk, CEO, Bionter; Asaf Zviran, CEO and co-founder of C2i Genomics; and Magali Bischof, secretary general of BioAlps. We also have our weekly commentary from Travis McCready at global commercial real estate services company JLL. This week’s podcast […]

The post Beyond Biotech podcast 30: Advanced Therapies Congress, BioAlps, Bionter, C2i Genomics appeared first on Labiotech.eu.

AstraZeneca’s Airsupra gets US approval as new rescue treatment for asthma

Jim Cornall — Wed, 11 Jan 2023 20:21:27 +0000

Avillion LLP says the US Food and Drug Administration (FDA) has approved AstraZeneca’s Airsupra for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. Airsupra, (albuterol/budesonide, formerly known as PT027) is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication […]

The post AstraZeneca’s Airsupra gets US approval as new rescue treatment for asthma appeared first on Labiotech.eu.

C2i Genomics extends AstraZeneca cancer deal

Jim Cornall — Fri, 06 Jan 2023 09:47:10 +0000

C2i Genomics, a cancer intelligence company, today announced an extension of a collaboration with AstraZeneca. The two companies have collaborated to evaluate the potential of whole-genome minimal residual disease (MRD) testing across solid cancers, with the goal of enhancing oncology treatment, supporting clinical trial recruitment, and monitoring. C2i genomics has completed AstraZeneca’s BeyondBio Innovation Hub’s […]

The post C2i Genomics extends AstraZeneca cancer deal appeared first on Labiotech.eu.

New targeted drug shows benefit against breast cancer in first phase III trial

Jim Cornall — Fri, 09 Dec 2022 11:32:52 +0000

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial. The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most common type of breast cancer. The findings, presented […]

The post New targeted drug shows benefit against breast cancer in first phase III trial appeared first on Labiotech.eu.

Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene

Jim Cornall — Fri, 09 Dec 2022 11:10:30 +0000

This week, we have three interviews. One is from Bio-Europe, a chat with Transgene chief business officer, Steven Bloom, and we also have conversations with Humacyte CEO Laura Niklason, and with Anthony McDonnell, Senior Policy Analyst at the Center for Global Development, on the subject of antimicrobial resistance. We also have our weekly commentary from […]

The post Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene appeared first on Labiotech.eu.

Enhertu’s positive results demonstrate improvement in overall survival

Liza Laws — Thu, 08 Dec 2022 22:48:23 +0000

Enhertu, an antibody drug conjugate, being jointly developed by Daiichi Sankyo and AstraZeneca, has demonstrated a statistically significant and clinically meaningful improvement in overall survival. Updated results from DESTINY-Breast03 phase 3 trial showed Enhertu (trastuzumab deruxtecan) was performing better than trastuzumab emtansine (T-DM1) in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated […]

The post Enhertu’s positive results demonstrate improvement in overall survival appeared first on Labiotech.eu.

AstraZeneca splashes out up to $320M on T-cell receptor therapy company

Jim Cornall — Wed, 30 Nov 2022 05:59:41 +0000

Neogene Therapeutics, Inc., a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts), has entered into a definitive agreement to be acquired by Astrazeneca. AstraZeneca will acquire all outstanding equity of Neogene Therapeutics for a total consideration of up to $320 million, on a cash and debt free […]

The post AstraZeneca splashes out up to $320M on T-cell receptor therapy company appeared first on Labiotech.eu.

Licensing agreement signed for C4XD between C4X Discovery and AstraZeneca

Liza Laws — Mon, 28 Nov 2022 09:51:41 +0000

C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca. It is worth up to $402 million, for its NRF2 Activator program. AstraZeneca will develop and commercialize an oral therapy, C4XD. This is for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD). C4X Discovery will receive […]

The post Licensing agreement signed for C4XD between C4X Discovery and AstraZeneca appeared first on Labiotech.eu.

AstraZeneca and Daiichi Sankyo’s Enhertu recommended for approval

Liza Laws — Thu, 17 Nov 2022 23:48:46 +0000

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) for patients previously treated HER-2 positive advanced gastric cancer. The drug is also used for gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialized by AstraZeneca […]

The post AstraZeneca and Daiichi Sankyo’s Enhertu recommended for approval appeared first on Labiotech.eu.

In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus

Jim Cornall — Mon, 14 Nov 2022 10:56:12 +0000

AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the European Union (EU) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. Beyfortus is the first and only single-dose RSV passive immunization for the broad infant population, including those born healthy, at term […]

The post In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus appeared first on Labiotech.eu.

Sanofi and AstraZeneca drug, Beyfortus, for RSV in babies and children approved

Liza Laws — Fri, 04 Nov 2022 16:18:44 +0000

A drug being developed jointly by Sanofi and AstraZeneca for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants was approved today (November 4). The European Commission has approved Beyfortus which is so far the first and only broadly protective option against the virus. Thomas Triomphe, executive vice president, […]

The post Sanofi and AstraZeneca drug, Beyfortus, for RSV in babies and children approved appeared first on Labiotech.eu.

Illumina and AstraZeneca look to drug target discovery with ‘pivotal research collaboration’

Jim Cornall — Tue, 11 Oct 2022 17:41:49 +0000

Illumina Inc. has announced a strategic research collaboration with AstraZeneca to accelerate drug target discovery by combining their work in artificial intelligence (AI) based genome interpretation and genomic analysis techniques along with industry expertise. The collaboration will evaluate whether a combined framework of these technologies can increase the yield and confidence of target discovery to […]

The post Illumina and AstraZeneca look to drug target discovery with ‘pivotal research collaboration’ appeared first on Labiotech.eu.